This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Why Is Idexx (IDXX) Up 3% Since Last Earnings Report?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now
by Zacks Equity Research
IDEXX (IDXX) registers strong revenue growth on the back of CAG Diagnostics.
Moving Average Crossover Alert: IDEXX Laboratories
by Zacks Equity Research
IDEXX Laboratories is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Idexx Laboratories (IDXX) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 12.50% and 0.83%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
IDEXX (IDXX) Q1 Earnings Top Estimates, EPS Guidance Up
by Zacks Equity Research
Strong sales at the CAG business favor IDEXX's (IDXX) top line in Q1.
Can Steady CAG Growth Drive IDEXX's (IDXX) Q1 Earnings?
by Zacks Equity Research
Idexx (IDXX) is expected to continue reporting solid revenue growth on robust CAG performance.
Idexx Laboratories (IDXX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock
by Zacks Equity Research
The innovation-based, multi-modality global strategy, enabled by enhanced commercial capability, accelerates IDEXX's (IDXX) recurring CAG Diagnostics revenue growth.
Neogen (NEOG) Earnings and Revenues Miss Estimates in Q3
by Zacks Equity Research
Continued weakness in the global animal protein market and strongly negative currency conversions posed as headwinds for Neogen (NEOG) in third-quarter fiscal 2019.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
A diversified product portfolio and strong Dental business prospects provide Patterson Companies (PDCO) a competitive edge in the MedTech space.
Here's Why You Should Invest in Integer Holdings (ITGR) Stock
by Zacks Equity Research
Integer Holdings (ITGR) is likely to gain from the Cardio & Vascular, Neuromodulation and Non-Medical Electrochem markets.
HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q4
by Zacks Equity Research
HealthEquity (HQY) witnesses strong HSA member growth in the fourth quarter of fiscal 2019.
Allscripts Partners With Opargo to Boost Practice Management
by Zacks Equity Research
Allscripts' (MDRX) partnership with Opargo is likely to improve scheduling capabilities and practice workflows of Allscripts Practice Management solution.
Stryker Buys Israel-Based OrthoSpace, Strengthens MedSurg
by Zacks Equity Research
Strong international presence and an acquisition-driven strategy are likely to fortify Stryker's (SYK) footprint in the global MedTech space.
Allscripts Strengthens Strategic Relationship with Pulse8
by Zacks Equity Research
Pulse8 is likely to boost Allscripts' (MDRX) flagship platform Veradigm, and its existing health plan product suite that delivers pocket-friendly tools and services for health plan members.
Here's Why Investors Should Retain McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) is well positioned for growth backed by strong business plans and robust surprise trend amid cutthroat competition in the near term.
Allscripts to Fortify Middle East Foothold With New Project
by Zacks Equity Research
Qatar-based Alfardan Group and Chicago-based Northwestern Medicine select Allscripts (MDRX) for the launch of a project in the Middle East.
Here's Why Investors Should Bet on Cooper Companies (COO) Now
by Zacks Equity Research
Cooper Companies (COO) maintains its leading position in the markets of specialty lenses. Further, the company exits first-quarter fiscal 2019 on a strong note.
Here's Why Investors Should Bet on Merit Medical (MMSI) Now
by Zacks Equity Research
Merit Medical's (MMSI) upbeat guidance for 2019 is indicative of the company's brighter prospects.
Baxter (BAX) Gets FDA Approval for Eptifibatide to Treat ACS
by Zacks Equity Research
Baxter's (BAX) Eptifibatide is a platelet aggregation inhibitor that prevents platelets-specialized blood cells clotting.
Here's Why You Should Invest in AngioDynamics Stock Now
by Zacks Equity Research
Expanding customer base of the NanoKnife platform is likely to fortify AngioDynamics' (ANGO) foothold in the Medical Instruments space.
Here's Why Momentum Investors Will Love Idexx Laboratories (IDXX)
by Zacks Equity Research
Does Idexx Laboratories (IDXX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock
by Zacks Equity Research
IDEXX (IDXX) continues to demonstrate solid growth globally, with strong international expansion.
Bright Near-Term Outlook for Medical Instruments Industry
by Zacks Equity Research
Growing medical awareness and economic prosperity have been enhancing the uptake of medical instruments in the emerging economies.